Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02591654 · ClinicalTrials.gov registry record · Early Phase 1
MRI and PET to Assess Pembrolizumab Response
A Early Phase 1 study, sponsored by Columbia University.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 6
- Enrollment target
NCT02591654: Clinical Trial Early Phase 1 study, sponsored by Columbia University.
NCT02591654 is a Early Phase 1 study that was terminated before completion, run by Columbia University. The registered enrollment target is 6 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02591654, a Early Phase 1 study, was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to test two imaging techniques, one called whole body (WB) diffusion weighted (DWI) magnetic resonance imaging (MRI) (WB-DWI MRI), and another called Fluorine-18 3'-deoxy-3'-fluorothymidine positron emission tomography (PET) (F-18-FLT PET). The goal is to see whether these imaging techniques would allow the study doctors to see changes in the size of a tumor earlier for patients with metastatic melanoma receiving Pembrolizumab (MK-3475).
Primary Outcome
Sensitivity of WB-DW MRI and FLT-PET imaging in lesion detection and evaluation for metastatic melanoma.
Interventions
- DRUG Pembrolizumab
- DRUG FLT PET
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2015-10 |
| Est. Completion | 2022-10 |
| Phase | Early Phase 1 |
Why NCT02591654 stopped before completion
NCT02591654 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02591654 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02591654 about?
NCT02591654 is a clinical study titled "MRI and PET to Assess Pembrolizumab Response". The purpose of this study is to test two imaging techniques, one called whole body (WB) diffusion weighted (DWI) magnetic resonance imaging (MRI) (WB-DWI MRI), and another called Fluorine-18 3'-deoxy-3'-fluorothymidine positron emission tomography (PET) (F-18-FLT PET). The goal is to see whether the...
What is the current status of trial NCT02591654?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2015-10. Estimated completion is 2022-10.
What interventions are being tested in trial NCT02591654?
The interventions under investigation include: Pembrolizumab (DRUG), FLT PET (DRUG).
Who is sponsoring clinical trial NCT02591654?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02591654's enrollment target sits among peer trials
6 1845th of 2000 higher than 114 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia